Clinical study of Qinggan Huashi Jiejiu Decoction combined with Tongluo Yanggan application in the treatment of alcoholic liver disease

Phase 1

• Conditions: alcoholic liver disease

• Registration Number: ITMCTR2022000106
• Lead Sponsor: Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the diagnostic criteria for alcoholic liver disease and have liver function ALT, AST or ?-GT greater than 1.5 times the normal value at the time of enrollment;
2. Meet the the syndrome differentiation criteria of Ganyu Pixu and Shire Neijie;
3. The age is between 18-65 years old, and the gender is not limited;
4. Willing to participate in this research and sign the informed consent.

Exclusion Criteria

1. Patients with other liver diseases such as hepatitis B and C;
2. Patients with autoimmune liver disease, drug-induced liver disease, toxic hepatitis, liver cancer, non-alcoholic fatty liver disease, occult hepatitis, and unexplained liver disease;
3. Pregnant or lactating women, those with allergic constitution;
4. Patients with mental disorders who cannot cooperate with this study;
5. Patients with severe heart, brain, lung, kidney, hematopoietic, immune and other system diseases;
6. Other conditions deemed inappropriate by the researcher.(including people with alcohol dependence)

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
lipid profile;liver function;CAP;LSM;liver ultrasound;